Sign in or create an account to add this stock to your watchlist.
About Ovid Therapeutics (NASDAQ:OVID)
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661
Debt
Debt-to-Equity RatioN/A
Current Ratio11.52
Quick Ratio11.52
Price-To-Earnings
Trailing P/E Ratio-2.47
Forward P/E Ratio-3.42
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.39 per share
Price / Book2.44
Profitability
EPS (Most Recent Fiscal Year)($3.35)
Net Income$-64,800,000.00
Net MarginsN/A
Return on Equity-50.09%
Return on Assets-46.83%
Miscellaneous
Employees43
Outstanding Shares24,620,000
Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions
What is Ovid Therapeutics' stock symbol?
Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
How were Ovid Therapeutics' earnings last quarter?
Ovid Therapeutics (NASDAQ:OVID) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.06. View Ovid Therapeutics' Earnings History.
When is Ovid Therapeutics' next earnings date?
What price target have analysts set for OVID?
6 brokerages have issued 1-year target prices for Ovid Therapeutics' stock. Their forecasts range from $20.00 to $27.00. On average, they expect Ovid Therapeutics' share price to reach $23.50 in the next year. View Analyst Ratings for Ovid Therapeutics.
Who are some of Ovid Therapeutics' key competitors?
Some companies that are related to Ovid Therapeutics include Assembly Biosciences (ASMB), Collegium Pharmaceutical (COLL), AMAG Pharmaceuticals (AMAG), Rhythm Pharmaceuticals (RYTM), Reata Pharmaceuticals (RETA), Deciphera Pharmaceuticals (DCPH), InflaRx (IFRX), Theratechnologies (THERF), Rocket Pharmaceuticals (RCKT), Dova Pharmaceuticals (DOVA), GlycoMimetics (GLYC), Amphastar Pharmaceuticals (AMPH), Vectura Group (VEGPF), ANI Pharmaceuticals (ANIP) and CymaBay Therapeutics (CBAY).
Who are Ovid Therapeutics' key executives?
Ovid Therapeutics' management team includes the folowing people:
- Dr. Jeremy Max Levin, Chairman and Chief Exec. Officer (Age 65)
- Dr. Amit Rakhit M.D., M.B.A., Chief Medical & Portfolio Management Officer (Age 48)
- Dr. Dirk Haasner Ph.D., MPM, Sr. VP of Global Regulatory Affairs & Manufacturing (Age 53)
- Dr. Matthew J. During M.D., DSc, FACP, FRACP, Founder, Pres, Chief Scientific Officer, Member of Scientific Advisory Board and Director (Age 61)
- Dr. Yaron Werber M.D., Chief Financial Officer, Chief Bus. Officer, Treasurer and Sec. (Age 46)
When did Ovid Therapeutics IPO?
(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
Has Ovid Therapeutics been receiving favorable news coverage?
News coverage about OVID stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ovid Therapeutics earned a coverage optimism score of 0.01 on Accern's scale. They also assigned media stories about the company an impact score of 44.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Ovid Therapeutics' major shareholders?
Ovid Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include TAKEDA PHARMACEUTICAL COMPANY LTD (7.20%), BlackRock Inc. (5.52%), Redmile Group LLC (0.65%), Northern Trust Corp (0.48%), Millennium Management LLC (0.24%) and Schwab Charles Investment Management Inc. (0.14%). View Institutional Ownership Trends for Ovid Therapeutics.
Which major investors are selling Ovid Therapeutics stock?
Which major investors are buying Ovid Therapeutics stock?
OVID stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Northern Trust Corp, JPMorgan Chase & Co., DRW Securities LLC, Schwab Charles Investment Management Inc., California State Teachers Retirement System and Spark Investment Management LLC. View Insider Buying and Selling for Ovid Therapeutics.
How do I buy shares of Ovid Therapeutics?
Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ovid Therapeutics' stock price today?
One share of OVID stock can currently be purchased for approximately $8.28.
How big of a company is Ovid Therapeutics?
Ovid Therapeutics has a market capitalization of $214.96 million. The company earns $-64,800,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Ovid Therapeutics employs 43 workers across the globe.
How can I contact Ovid Therapeutics?
Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]
MarketBeat Community Rating for Ovid Therapeutics (OVID)
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ovid Therapeutics (NASDAQ:OVID) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Ovid Therapeutics in the last 12 months. Their average twelve-month price target is $23.50, suggesting that the stock has a possible upside of 183.82%. The high price target for OVID is $27.00 and the low price target for OVID is $20.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.50 | $23.50 | $23.50 | $23.50 |
| Price Target Upside: | 183.82% upside | 129.27% upside | 62.29% upside | 62.29% upside |
Ovid Therapeutics (NASDAQ:OVID) Consensus Price Target History
Ovid Therapeutics (NASDAQ:OVID) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Ovid Therapeutics (NASDAQ:OVID) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ovid Therapeutics (NASDAQ OVID) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 43.90%
Institutional Ownership Percentage: 29.26%
Ovid Therapeutics (NASDAQ OVID) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/25/2017 | Jeremy M Levin | CEO | Buy | 15,334 | $7.15 | $109,638.10 | 4,601,529 |  |
(Data available from 1/1/2013 forward)
Ovid Therapeutics (NASDAQ OVID) News Headlines
| Source: |
|
Ovid Therapeutics (NASDAQ:OVID) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ovid Therapeutics (NASDAQ:OVID) Income Statement, Balance Sheet and Cash Flow Statement
Ovid Therapeutics (NASDAQ OVID) Stock Chart for Monday, May, 21, 2018
Loading chart…
